Logo do repositório
 
Publicação

Old molecules, new hope: a scoping review and bibliometric analysis of drug repurposing for lung cancer

2026-06Artigo científico Acesso aberto
Ver registo simples
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorRagassi, Wellington Martins
dc.contributor.authorAlves, Fernando Miguel
dc.contributor.authorLazo, Raul Edison
dc.contributor.authorTonin, Fernanda
dc.contributor.authorPontarolo, Roberto
dc.contributor.authorSari, Marcel Henrique
dc.contributor.authorFerreira, Luana Mota
dc.date.accessioned2026-04-14T08:54:10Z
dc.date.available2026-04-14T08:54:10Z
dc.date.issued2026-06
dc.descriptionWe gratefully acknowledge Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES-BR) for the fellowships received by Wellington Martins de Carvalho Ragassi (#V1 - CAPES – DS), and the National Council for Scientific and Technological Development (CNPq) for the fellowships received by Fernando Miguel Stelmach Alves (PIBIC). This study is part of the National Institute of Science and Technology in 3D printing and Advanced Materials Applied to Human and Veterinary Health—INCT_3D-Saúde, funded by CNPq, Brazil (Grant #406436/2022–3).
dc.description.abstractDrug repurposing has gained prominence in oncology by enabling the investigation of approved drugs for new therapeutic purposes. In lung cancer, this strategy may reduce the time and costs associated with drug development. This study aimed to map the landscape of in silico, in vitro, in vivo, and clinical research on drug repurposing for lung cancer, while identifying key molecular targets and research gaps. A systematic search was conducted in PubMed, Embase, and Web of Science, following Joanna Briggs Institute and PRISMA-ScR guidelines. Two reviewers independently selected and extracted the data. A total of 58 studies, published between 2010 and 2024, mainly from the United Kingdom (19%) and the United States (17%), were included. Most studies used in vitro models (53%), followed by in vivo (31%) and in silico (16%), with frequent combinations of methods. The most investigated drug classes were antibiotics (10%), antipsychotics (9%), antidiabetics (8%), anthelmintics (6%), and antihistamines (6%). Frequently studied drugs included niclosamide, metformin, atorvastatin, and doxazosin, targeting pathways such as PI3K/AKT/mTOR, apoptosis, and autophagy. Bibliometric analysis revealed increasing scientific output, with emphasis on combination therapies, cellular mechanisms, and technologies like molecular docking and nanosystems. These findings highlight the growing relevance of drug repurposing in lung cancer, especially in accelerating effective therapy discovery using approved compounds. Progress in this field depends on integrating diverse methodologies and fostering interdisciplinary collaboration. As a next step, rigorous clinical trials are essential to confirm the efficacy and safety of promising repurposed agents in oncology.eng
dc.identifier.citationRagassi WM, Alves FM, Lazo RE, Tonin FS, Pontarolo R, Sari MH, et al. Old molecules, new hope: a scoping review and bibliometric analysis of drug repurposing for lung cancer. Chem Biol Interact. 2026;432:112048.
dc.identifier.doi10.1016/j.cbi.2026.112048
dc.identifier.issn0009-2797
dc.identifier.urihttp://hdl.handle.net/10400.21/22780
dc.language.isoeng
dc.peerreviewedyes
dc.publisherElsevier BV
dc.relation.hasversionhttps://www.sciencedirect.com/science/article/pii/S0009279726001560
dc.relation.ispartofChemico-Biological Interactions
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCancer
dc.subjectDrug reprofiling
dc.subjectNon-small cell lung cancer
dc.subjectTherapeutic innovation
dc.subjectLung cancer
dc.titleOld molecules, new hope: a scoping review and bibliometric analysis of drug repurposing for lung cancereng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.startPage112048
oaire.citation.titleChemico-Biologal Interactions
oaire.citation.volume432
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameTonin
person.givenNameFernanda
person.identifier.ciencia-idD01C-C700-9411
person.identifier.orcid0000-0003-4262-8608
person.identifier.ridO-2050-2017
person.identifier.scopus-author-id56085115800
relation.isAuthorOfPublication61ded30e-ecec-4b3e-b953-2293e080ebdd
relation.isAuthorOfPublication.latestForDiscovery61ded30e-ecec-4b3e-b953-2293e080ebdd

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Old molecules, new hope_a scoping review and bibliometric analysis of drug repurposing for lung cancer.pdf
Tamanho:
4.21 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

ESTeSL - Artigos